LONDON (Reuters) - Shares in AstraZeneca fell more than 5 percent on Thursday after the company declined to deny a media report that Chief Executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical Industries.
AstraZeneca slumps on report CEO is heading to Teva
Read More
Bagikan Berita Ini
Langganan:
Posting Komentar (Atom)
0 Response to "AstraZeneca slumps on report CEO is heading to Teva"
Posting Komentar